Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05986292 · ClinicalTrials.gov registry record · Phase 2

A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

A Phase 2 study of Osteoarthritis, Knee and Chronic Low Back Pain, sponsored by Eli Lilly and Company.

Recruiting
Registry status
Phase 2
Development phase
10,000
Enrollment target
20
Study locations

NCT05986292 is a Phase 2 study of Osteoarthritis, Knee and Chronic Low Back Pain that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 10,000 participants, above the 470-participant average among 91 other Osteoarthritis, Knee trials with a reported enrollment target (2028% higher). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05986292, a Phase 2 study of Osteoarthritis, Knee and Chronic Low Back Pain, is actively recruiting participants, sponsored by Eli Lilly and Company.

RECRUITING
Registry status
Phase 2
Development phase
10,000 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.

Interventions

  • DRUG LY3016859 ISA
  • DRUG LY3556050 ISA
  • DRUG LY3526318 ISA
  • DRUG LY3857210 ISA
  • DRUG Placebo Oral

Study Locations (20)

Florida

  • VIN-Julie Schwartzbard - Aventura
  • Bradenton Research Center, Inc. - Bradenton
  • Clinical Research of South Florida - Coral Gables
  • Accel Research Sites - DeLand Clinical Research Unit - DeLand
  • K2 MEDICAL Research THE VILLAGES - Lady Lake
  • K2 Medical Research ORLANDO - Maitland
  • Merritt Island Medical Research, LLC - Merritt Island
  • Flourish Research - Miami, LLC - Miami
  • University of Miami Don Suffer Clinical Research Building - Miami

Arizona

  • Synexus Clinical Research - Glendale - Glendale
  • Central Phoenix Medical Clinic - Phoenix
  • Arizona Research Center - Phoenix
  • Alliance for Multispecialty Research, LLC - Tempe

California

  • Irvine Clinical Research - Irvine
  • Desert Oasis Healthcare Medical Group - Palm Springs
  • Artemis Institute for Clinical Research - Riverside
  • Artemis Institute for Clinical Research - San Diego

Alabama

  • Central Research Associates - Birmingham
  • Simon Williamson Clinic - Birmingham

Connecticut

  • CMR of Greater New Haven - Hamden

Trial Details

FieldValue
Enrollment Target 10,000 participants
Start Date 2020-01-30
Est. Completion 2027-04
Phase Phase 2

Sponsor

Eli Lilly and Company

1,341 total trials

What the Registry Record Tells You About NCT05986292

The ClinicalTrials.gov registry entry for NCT05986292 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 470-participant average among 91 other Osteoarthritis, Knee trials with a reported enrollment target (2028% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Osteoarthritis, Knee appearing as the primary indexed condition, and to 5 interventions - of which LY3016859 ISA is the first listed.

NCT05986292 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT05986292 about?

NCT05986292 is a clinical study titled "A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain". The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for cl...

What is the current status of trial NCT05986292?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10,000 participants. The study started on 2020-01-30. Estimated completion is 2027-04.

What conditions does trial NCT05986292 study?

This clinical trial studies the following conditions: Osteoarthritis, Knee, Chronic Low Back Pain, Diabetic Neuropathic Pain.

What interventions are being tested in trial NCT05986292?

The interventions under investigation include: LY3016859 ISA (DRUG), LY3556050 ISA (DRUG), LY3526318 ISA (DRUG), LY3857210 ISA (DRUG), Placebo Oral (DRUG).

Who is sponsoring clinical trial NCT05986292?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05986292 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis, Knee

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.